Targeting B7-H3 in solid tumors: Development and evaluation of novel CAR-T Cell therapy

被引：0

作者：

Li, Ning ^{[1
]}

Zhang, Chunhua ^{[1
,2
]}

Li, Xiaoyu ^{[3
]}

Liu, Shufen ^{[4
]}

Xu, Youhua ^{[1
]}

Yang, Xifei ^{[1
,5
]}

机构：

[1] Macau Univ Sci & Technol, Fac Chinese Med, Taipa 999078, Macao, Peoples R China

[2] Nanjing Med Univ, Affiliated Hosp 2, Nanjing 210000, Peoples R China

[3] Chongqing Univ, Coll Mech & Vehicle Engn, Chongqing 400030, Peoples R China

[4] Hengshui Peoples Hosp, Surg Intervent Dept, Hengshui 053000, Hebei, Peoples R China

[5] Shenzhen Ctr Dis Control & Prevent, Key Lab Modern Toxicol Shenzhen, 8 Longyuan Rd, Shenzhen 518055, Peoples R China

来源：

IMMUNOBIOLOGY | 2025年 / 230卷 / 03期

关键词：

B7-H3; CAR-T cells; Solid tumors; Tumor microenvironment; Immunotherapy; CANCER-IMMUNOTHERAPY;

D O I：

10.1016/j.imbio.2025.152888

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Ovarian and gastric cancers, representative of many solid tumors, remain among the most challenging malignancies to treat due to limited therapeutic options and poor outcomes at advanced stages. Although immunotherapies have revolutionized cancer treatment, their efficacy in solid tumors has been hindered by issues such as antigen heterogeneity and the immunosuppressive tumor microenvironment. This study presents the development and evaluation of third-generation chimeric antigen receptor T (CAR-T) cells targeting B7-H3, an immune checkpoint molecule widely overexpressed in solid tumors. The B7-H3 CAR-T cells exhibited robust and selective cytotoxicity against B7-H3-positive tumor cells, sparing normal tissues. In preclinical animal models, these cells significantly inhibited tumor growth, demonstrating higher targeting specificity and preferential accumulation in tumor sites. These results highlight B7-H3-targeted CAR-T cells as a potential breakthrough in immunotherapy for solid tumors, offering a foundation for future clinical trials to refine their safety and efficacy.

引用

页数：9

共 34 条

[1] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].

Bang, Yung-Jue ;

Van Cutsem, Eric ;

Feyereislova, Andrea ;

Chung, Hyun C. ;

Shen, Lin ;

Sawaki, Akira ;

Lordick, Florian ;

Ohtsu, Atsushi ;

Omuro, Yasushi ;

Satoh, Taroh ;

Aprile, Giuseppe ;

Kulikov, Evgeny ;

Hill, Julie ;

Lehle, Michaela ;

Ruschoff, Josef ;

Kang, Yoon-Koo .

LANCET, 2010, 376 (9742) :687-697

[2] Toxicities of chimeric antigen receptor T cells: recognition and management [J].

Brudno, Jennifer N. ;

Kochenderfer, James N. .

BLOOD, 2016, 127 (26) :3321-3330

[3] Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains [J].

Carpenito, Carmine ;

Milone, Michael C. ;

Hassan, Raffit ;

Simonet, Jacqueline C. ;

Lakhal, Mehdi ;

Suhoski, Megan M. ;

Varela-Rohena, Angel ;

Haines, Kathleen M. ;

Heitjan, Daniel F. ;

Albelda, Steven M. ;

Carroll, Richard G. ;

Riley, James L. ;

Pastan, Ira ;

June, Carl H. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (09) :3360-3365

[4] ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease [J].

Colombo, N. ;

Sessa, C. ;

du Bois, A. ;

Ledermann, J. ;

McCluggage, W. G. ;

McNeish, I. ;

Morice, P. ;

Pignata, S. ;

Ray-Coquard, I. ;

Vergote, I. ;

Baert, T. ;

Belaroussi, I. ;

Dashora, A. ;

Olbrecht, S. ;

Planchamp, F. ;

Querleu, D. ;

Baert, T. ;

Banerjee, S. ;

Belaroussi, I. ;

Blecharz, P. ;

Bruchim, I. ;

Cibula, D. ;

Colombo, N. ;

Concin, N. ;

Davidson, B. ;

Dashora, A. ;

Devouassoux-Shisheboran, M. ;

du Bois, A. ;

Ferrero, A. ;

Glasspool, R. ;

Gonzalez-Martin, A. ;

Heinzelmann-Schwarz, V. ;

Joly, F. ;

Kim, J. W. ;

Kridelka, F. ;

Ledermann, J. ;

Lorusso, D. ;

Mahner, S. ;

McCluggage, W. G. ;

McNeish, I. ;

Mikami, M. ;

Mirza, M. R. ;

Morice, P. ;

Nicum, S. ;

Olbrecht, S. ;

O'Donnell, D. M. ;

Pautier, P. ;

Planchamp, F. ;

Pignata, S. ;

Querleu, D. .

ANNALS OF ONCOLOGY, 2019, 30 (05) :672-705

[5] CAR-T cell manufacturing landscape-Lessons from the past decade and considerations for early clinical development [J].

Dias, Juliana ;

Garcia, John ;

Agliardi, Giulia ;

Roddie, Claire .

MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2024, 32 (02)

[6] Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells [J].

Flem-Karlsen, Karine ;

Tekle, Christina ;

Andersson, Yvonne ;

Flatmark, Kjersti ;

Fodstad, Oystein ;

Nunes-Xavier, Caroline E. .

PIGMENT CELL & MELANOMA RESEARCH, 2017, 30 (05) :467-476

[7] Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts [J].

Hartmann, Jessica ;

Schuessler-Lenz, Martina ;

Bondanza, Attilio ;

Buchholz, Christian J. .

EMBO MOLECULAR MEDICINE, 2017, 9 (09) :1183-1197

[8] Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy [J].

Hawkins, Elizabeth R. ;

D'Souza, Reena R. ;

Klampatsa, Astero .

BIOLOGICS-TARGETS & THERAPY, 2021, 15 :95-105

[9] T cell exclusion, immune privilege, and the tumor microenvironment [J].

Joyce, Johanna A. ;

Fearon, Douglas T. .

SCIENCE, 2015, 348 (6230) :74-80

[10] Chimeric Antigen Receptor Therapy [J].

June, Carl H. ;

Sadelain, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :64-73

← 1 2 3 4 →